Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study
ClinicalTrials.gov Identifier: NCT04895202
Novartis Reference Number: CBAF312ACH01
Last Update: Dec 23, 2022
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label.
Interventions
Eligibility Criteria
Inclusion Criteria:
Signed informed consent
Adult patients with a documented diagnosis of SPMS with inflammatory disease activity who are going to be treated with Siponimod under routine medical care and in accordance with the Swiss label
Patient willing and able to complete the questionnaires
Exclusion Criteria:
Patients treated outside of the approved Swiss label for Siponimod
Prior treatment or already ongoing treatment with Siponimod
Use of investigational drugs during the study, OR within 3 months before enrollment, OR within 5 half-lives of investigational drug before enrollment, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer
Subjects who are not able to provide consent due to incapable judgement
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]